The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole

被引：0
|
作者：
Bekkers, CHJ
Touw, DJ
Lamers, CBHW
Geus, WP
机构：
[1] Hague Cent Pharm, The Hague, Netherlands
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Leyenburg Hosp, The Hague, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [41] EFFECT OF CYP2C19 POLYMORPHISM ON THE PHARMACOKINETICS OF ROSUVASTATIN IN HEALTHY TAIWANESE SUBJECTS.
    Wang, Y.
    Wang, T.
    Finkelman, R. D.
    Jou, H.
    Azumaya, C. T.
    Mosqueda-Garcia, R.
    Birmingham, B. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S22 - S22
  • [42] Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism
    Takahashi, K
    Motohashi, H
    Yonezawa, A
    Okuda, M
    Ito, N
    Yamamoto, S
    Ogawa, O
    Inui, K
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 791 - 794
  • [43] Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis
    Koike, Tomoyuki
    Iijima, Katsunori
    Imatani, Akira
    Shimosegawa, Tooru
    GASTROENTEROLOGY, 2010, 138 (05) : S655 - S655
  • [44] The effect of famotidine on the acid inhibition by lansoprazole in relation to CYP2C19 genotype status.
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Okudaira, K
    Kajimura, M
    Hishida, A
    GASTROENTEROLOGY, 2005, 128 (04) : A426 - A426
  • [45] Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Hishida, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 361 - 361
  • [46] Lansoprazole + clarithromycin: interaction independent of CYP2C19
    Reactions Weekly, 2005, 1052 (1) : 3 - 3
  • [47] Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect
    Kearns, Gregory L.
    Leeder, J. Steven
    Gaedigk, Andrea
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (06) : 894 - 897
  • [48] Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
    Kamiya, Chiaki
    Inui, Naoki
    Hakamata, Akio
    Miyakawa, Sachiko
    Tanaka, Shimako
    Uchida, Shinya
    Namiki, Noriyuki
    Odagiri, Keiichi
    Watanabe, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2019, 139 (04) : 361 - 366
  • [49] THE EFFECT OF CYP2C19 POLYMORPHISM ON THE PHARMACOKINETICS AND TOLERABILITY OF VORICONAZOLE AFTER MULTIPLE ORAL ADMINISTRATIONS IN HEALTHY VOLUNTEERS.
    Lee, S.
    Kim, B. H.
    Nam, W. S.
    Kim, S. J.
    Shim, J. H.
    Yoon, S. H.
    Cho, J. Y.
    Shin, S. G.
    Jang, I. J.
    Yu, K. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S26 - S27
  • [50] Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects (vol 41, pg 511, 2011)
    Zhang, Dan
    Wang, Xiaolin
    Yang, Man
    Wang, Guocai
    Liu, Huichen
    XENOBIOTICA, 2011, 41 (09) : 836 - 836
12345